Skip to content
drillr.ai
Sign up

GYRE

Gyre Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$6.86
+6.52%
Ask drillr

  • Aug 7, 2026, 11:00 UTC

    Gyre Therapeutics reported second quarter 2026 revenue of $29.1 million and a GAAP basic loss per share of $0.12.

    Source: